Nagler A - Search Results

1

Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization.

Amiel A, Yarkoni S, Slavin S, Or R, Lorberboum-Galski H, Fejgin M, Nagler A. Amiel A, et al. Among authors: nagler a. Cancer Genet Cytogenet. 1994 Aug;76(1):59-64. doi: 10.1016/0165-4608(94)90073-6. Cancer Genet Cytogenet. 1994. PMID: 8076354

2

Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization.

Nagler A, Slavin S, Yarkoni S, Fejgin M, Amiel A. Nagler A, et al. Cancer Genet Cytogenet. 1994 Apr;73(2):130-3. doi: 10.1016/0165-4608(94)90196-1. Cancer Genet Cytogenet. 1994. PMID: 8174087

3

Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia.

Amiel A, Yarkoni S, Fejgin M, Gaber E, Nagler A, Manor Y, Lishner M. Amiel A, et al. Among authors: nagler a. Cancer Genet Cytogenet. 1993 Jan;65(1):32-4. doi: 10.1016/0165-4608(93)90055-q. Cancer Genet Cytogenet. 1993. PMID: 8431913

4

Low molecular weight heparin for Hickman catheter--induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation.

Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor A. Drakos PE, et al. Among authors: nagler a. Cancer. 1992 Oct 1;70(7):1895-8. doi: 10.1002/1097-0142(19921001)70:7<1895::aid-cncr2820700715>3.0.co;2-i. Cancer. 1992. PMID: 1326397

5

Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).

Slavin S, Or R, Kapelushnik Y, Drakos P, Ackerstein A, Vourka-Karussis U, Weiss L, Nagler A. Slavin S, et al. Among authors: nagler a. Leukemia. 1992 Nov;6 Suppl 4:164-6. Leukemia. 1992. PMID: 1434823 Clinical Trial.

6

Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.

Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E. Slavin S, et al. Among authors: nagler a. Cancer Invest. 1992;10(3):221-7. doi: 10.3109/07357909209032764. Cancer Invest. 1992. PMID: 1581831 Clinical Trial.

7

Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.

Nagler A, Ackerstein A, Barak V, Slavin S. Nagler A, et al. J Hematother. 1994 Spring;3(1):75-82. doi: 10.1089/scd.1.1994.3.75. J Hematother. 1994. PMID: 7922012 Clinical Trial.

8

Systemic chimerism in sex-mismatched liver transplant recipients detected by fluorescence in situ hybridization.

Nagler A, Ilan Y, Amiel A, Eid A, Tur-Kaspa R. Nagler A, et al. Transplantation. 1994 May 27;57(10):1458-61. Transplantation. 1994. PMID: 8197608

9

Predominant 45,X,--Y karyotype in donor cells after allogeneic BMT: cytogenetic and molecular analysis.

Abeliovich D, Yehuda O, Nagler A, Lerer I, Ben-Neriah S, Amar A, Or R. Abeliovich D, et al. Among authors: nagler a. Cancer Genet Cytogenet. 1996 Jan;86(1):1-7. doi: 10.1016/0165-4608(95)00170-0. Cancer Genet Cytogenet. 1996. PMID: 8616777

10

B-cell non-Hodgkin's lymphoma: evidence for the t (14;18) translocation in all hematopoietic cell lineages.

Yarkoni S, Lishner M, Tangi I, Nagler A, Lorberboum-Galski H. Yarkoni S, et al. Among authors: nagler a. J Natl Cancer Inst. 1996 Jul 17;88(14):973-9. doi: 10.1093/jnci/88.14.973. J Natl Cancer Inst. 1996. PMID: 8667428

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,463 results

Search Page

Filters